SCHEMBL14725592

SCHEMBL14725592

CCC(C)(CC(C)(CC(C)(C)C(=O)NCCCCCC(=O)NC)C(=O)OCCCC=O)C(=O)NCC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14725590 0.81 — —
SCHEMBL14725593 0.78 — —
SCHEMBL16233285 0.67 CYP4F2 (0.36) —
SCHEMBL23735528 0.65 EPHX2 (0.53) —
SCHEMBL26420456 0.65 ACHE (0.39) —
SCHEMBL19821859 0.63 EPHX1 (0.37) —
SCHEMBL12913887 0.62 PKM (0.30) —
SCHEMBL25976942 0.62 TSHR (0.44) —
SCHEMBL27383505 0.62 TSHR (0.44) —
SCHEMBL24216138 0.62 TSHR (0.44) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9198972-B2 Monomers and oligonucleotides comprising cycloaddition adduct(s) ALNYLAM PHARMACEUTICALS, INC. (US) 2015-12-01 — — US disclosed
US-20130053334-A1 MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) ALNYLAM PHARMACEUTICALS, INC. (US) 2013-02-28 — — US disclosed
Send feedback